CPDD 78th Annual Scientific Meeting Program

Wednesday, June 15, 2016
7 A randomized trial of patient-centered methadone treatment with optional counseling
R. P. Schwartz 1 , S. M. Kelly 1 , J. Gryczynski 1 , K. O’Grady 2 , D. Gandhi 4 , Y. Olsen 3 , J. H. Jaffe 1 ,
S. G. Mitchell 1 , 1 Friends Research Institute, Baltimore, MD, 2 Univ. of Maryland, College
Park, MD, 3 IRB REACH, Baltimore, MD, 4 Psychiatry, Univ. of Maryland, Baltimore, MD
8 Fair hearing outcomes for patients recommended discharge from methadone maintenance
J. S. Chang, J. Chiu, V. Gruber, J. Sorensen, U.C. San Francisco, San Francisco, CA
9 A systematic review of opioid agonist treatments for pharmaceutical opioid dependence
S. Nielsen 3,2 , B. Larance 3 , L. Degenhardt 3 , L. Gowing 1 , N. Lintzeris 2,4 , 1 University of Adelaide,
Adelaide, SA, Australia, 2 South Eastern Sydney Local Health District, Sydney, NSW,
Australia, 3 UNSW Australia, Sydney, NSW, Australia, 4 University of Sydney, Sydney, NSW,
Australia
10 The impact of psychopharmacotherapy on disenrollment from office-based opioid treatment
with buprenorphine
Z. M. Weinstein 1,2 , D. M. Cheng 1 , E. Quinn 1 , D. Hui 1 , H. Kim 1 , G. Gryczynski 1,2 , C. Labelle 1,2 ,
J. H. Samet 1,2 , 1 Boston University, Boston, MA, 2 Boston Medical Center, Boston, MA
11 Urine drug testing for patients on buprenorphine: Informative beyond self-reported cocaine and
opioid use?
S. M. Bagley 2 , D. M. Cheng 4 , M. R. Winter 4 , D. Alford 3 , C. Labelle 3 , A. Y. Walley 1 ,
J. H. Samet 3 , 1 General Internal Medicine, Boston Univ, Boston, MA, 2 Medicine, Boston
University School of Medicine, Boston, MA, 3 Boston University Medical Center/Boston
Medical Center, Boston, MA, 4 Boston University School of Public Health, Boston, MA
12 Within-subject evaluation of interim buprenorphine vs. waitlist on illicit opioid use
T. A. Ochalek 5 , J. D. Pusey 5 , B. Hruska 1 , S. H. Heil 1 , S. Higgins 1 , G. Rose 1 , B. A. Moore 4 ,
S. C. Sigmon 1 , 1 Psychiatry, The University of Vermont, Burlington, VT, 4 Psychiatry, Yale
University School of Medicine, New Haven, CT, 5 Psychology, University of Vermont,
Burlington, VT
13 Safety of combination buprenorphine/naloxone and extended-release naltrexone
R. Lindblad 1 , A. Saxon 3 , P. VanVeldhuisen 1 , L. Lu 1 , L. Hu 1 , A. Hasson 2 , C. Thomas 2 ,
S. Sparenborg 4 , L. Mooney 2 , W. Ling 2 , 1 EMMES, Rockville, MD, 2 UCLA, Los Angeles, CA,
3
VA, Seattle, WA, 4 NIDA, Rockville, MD
14 “The devil I know is better than the devil I don’t know”: Enrollment in a pilot trial of opioid
dose escalation vs. buprenorphine/naloxone for pain
A. Manhapra, D. A. Fiellin, W. Becker, Yale University, New Haven, CT
15 Improving buprenorphine treatment outcomes with the L-type calcium channel blocker
isradipine
A. Oliveto 1 , J. McGaugh 1 , J. B. Guise 1 , J. D. Thostenson 2 , M. J. Mancino 1 , 1 Psychiatry,
University of Arkansas for Medical Sciences, Little Rock, AR, 2 Biostatistics, University of
Arkansas for Medical Sciences, Little Rock, AR
16 Sensitivity analysis of a comparative trial of 6-month buprenorphine implants (Probuphine) and
sublingual buprenorphine in stable opioid-dependent patients
R. Rosenthal 2 , M. R. Lofwall 1 , S. Kim 3 , M. Chen 4 , K. Beebe 5 , F. Vocci 6 , 1 University of
Kentucky, Lexington, KY, 2 Psychiatry, Icahn School of Medicine, New York, NY, 3 Braeburn
Pharmaceuticals, Princeton, NJ, 4 TCM Groups, Berkeley Heights, NJ, 5 Titan Pharmaceuticals,
South San Francisco, CA, 6 Friends Research Institute, Baltimore, MD
77